Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ-inducing property
- 31 December 2005
- journal article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 64 (3), 476-478
- https://doi.org/10.1016/j.mehy.2004.09.015
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
This publication has 12 references indexed in Scilit:
- ARBs and target organ protectionPostgraduate Medicine, 2004
- Peroxisome Proliferator-Activated Receptors and AtherogenesisCirculation Research, 2004
- Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ ActivityCirculation, 2004
- Impact of the renin-angiotensin system on lipid and carbohydrate metabolismCurrent Opinion in Nephrology and Hypertension, 2004
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Insulin resistance and hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Challenges in improving prognosis and therapy: The Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial ProgrammeExpert Opinion on Pharmacotherapy, 2004
- Insulin and insulin resistance:: impact on blood pressure and cardiovascular diseaseMedical Clinics of North America, 2004
- Atherosclerosis in Type 2 Diabetes Mellitus: The Role of Insulin ResistanceJournal of Cardiovascular Pharmacology and Therapeutics, 2003
- Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: A review of the clinical trial evidenceClinical Therapeutics, 2003